United Asset Strategies Inc. Has $504,000 Stake in Becton, Dickinson and Company $BDX

13 Nov 2025, 09:16 by Amy Steele · The Cerbat Gem

United Asset Strategies Inc. cut its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 82.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,929 shares of the medical instruments supplier’s stock after selling 13,606 shares during the period. United Asset Strategies Inc.’s holdings in Becton, Dickinson and Company were worth $504,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the last quarter. Edgestream Partners L.P. grew its stake in shares of Becton, Dickinson and Company by 28.8% during the first quarter. Edgestream Partners L.P. now owns 7,130 shares of the medical instruments supplier’s stock worth $1,633,000 after buying an additional 1,596 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at $252,000. Whittier Trust Co. of Nevada Inc. increased its holdings in Becton, Dickinson and Company by 7.2% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 7,537 shares of the medical instruments supplier’s stock worth $1,726,000 after purchasing an additional 503 shares in the last quarter. Finally, Wealthfront Advisers LLC grew its holdings in shares of Becton, Dickinson and Company by 53.2% during the first quarter. Wealthfront Advisers LLC now owns 7,960 shares of the medical instruments supplier’s stock worth $1,823,000 after purchasing an additional 2,764 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Morgan Stanley boosted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Stifel Nicolaus cut their price target on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a research report on Friday, November 7th. Finally, Piper Sandler lowered their price objective on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $203.27.

Read Our Latest Stock Analysis on Becton, Dickinson and Company

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 217 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director owned 35,816 shares in the company, valued at $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 1,249 shares of company stock valued at $231,358. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $192.03 on Thursday. The company has a market cap of $55.04 billion, a P/E ratio of 34.54, a PEG ratio of 1.42 and a beta of 0.25. The company has a fifty day simple moving average of $186.61 and a 200 day simple moving average of $181.95. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $162.29 and a 12-month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion for the quarter. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be paid a dividend of $1.05 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date is Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

Becton, Dickinson and Company Company Profile

(Free Report)